Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Ganglioneuroblastoma 3Vaginal Neoplasms 2Neuroblastoma 2Wilms Tumor 1Thoracic Diseases 1Testicular Neoplasms 1Teratoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Germ Cell Cancer 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Endodermal Sinus Tumor 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Erlotinib Hydrochloride 2dehydroftorafur 1X-Rays 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Immunohistochemistry 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Congresses as Topic 1Capecitabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreatic Intraductal Neoplasms × Congresses as Topic × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡